106 related articles for article (PubMed ID: 7808966)
1. Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases.
Haerslev T; Jacobsen K; Nedergaard L; Zedeler K
Pathol Res Pract; 1994 Aug; 190(7):675-81. PubMed ID: 7808966
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas.
Haerslev T; Jacobsen GK; Zedeler K
APMIS; 1995 Apr; 103(4):279-85. PubMed ID: 7612258
[TBL] [Abstract][Full Text] [Related]
4. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis.
Oyama T; Take H; Hikino T; Iino Y; Nakajima T
Oncology; 1996; 53(2):112-7. PubMed ID: 8604236
[TBL] [Abstract][Full Text] [Related]
6. [Proliferation index and its prognostic value in invasive ductal breast carcinoma].
Falco M
Ann Acad Med Stetin; 2009; 55(1):22-30. PubMed ID: 20349588
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of metallothionein predicts chemoresistance in breast cancer.
Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH
J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991
[TBL] [Abstract][Full Text] [Related]
8. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
9. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer.
Miyake M; Nakano K; Itoi SI; Koh T; Taki T
Cancer Res; 1996 Mar; 56(6):1244-9. PubMed ID: 8640807
[TBL] [Abstract][Full Text] [Related]
10. Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis.
Park D; Kåresen R; Axcrona U; Noren T; Sauer T
APMIS; 2007 Jan; 115(1):52-65. PubMed ID: 17223851
[TBL] [Abstract][Full Text] [Related]
11. Localization of metallothionein in breast carcinomas. An immunohistochemical study.
Fresno M; Wu W; Rodriguez JM; Nadji M
Virchows Arch A Pathol Anat Histopathol; 1993; 423(3):215-9. PubMed ID: 8236816
[TBL] [Abstract][Full Text] [Related]
12. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue].
Schulze MH; Buchmann J
Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
14. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
15. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.
Barth A; Craig PH; Silverstein MJ
Cancer; 1997 May; 79(10):1918-22. PubMed ID: 9149018
[TBL] [Abstract][Full Text] [Related]
16. Metallothionein expression in invasive and in situ breast carcinomas.
Gallicchio LM; Flaws JA; Fowler BA; Ioffe OB
Cancer Detect Prev; 2005; 29(4):332-7. PubMed ID: 16122884
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemical detection and prognostic significance of p53 in the primary tumor of breast carcinoma patients].
Beck T; Weller E; Weikel W; Brumm C; Wilkens C; Knapstein PG
Geburtshilfe Frauenheilkd; 1995 May; 55(5):252-7. PubMed ID: 7607381
[TBL] [Abstract][Full Text] [Related]
19. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
